There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors.
Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy
Lambertini, Matteo;
2021-01-01
Abstract
There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
